Tung X Nguyen
Serhat Gümrükcü 1, Tung X Nguyen 1,2, Michael Bobardt 3, Joseph Kuo 3, Phillip Musikanth 1, Philippe Gallay 3, 1Seraph Research Institute, Los Angeles, CA; 2Enochian Biosciences, Los Angeles, CA: 3Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, CA
• Despite an effective vaccine, approximately 5 percent of the world’s population chronically carry hepatitis B virus (HBV) and nearly 1 million people die each year.
• Several promising avenues for treatment have been pursued including depleting the pool of
covalently closed circular (ccc)DNA and inhibiting HBV polymerase (HBV pol), which is essential
both for its reverse transcription and packaging functions.
• In this study, rather than trying to inhibit the HBV life cycle, we utilize the virus and cellular
machinery to kill the infected cells as a potential cure.
MECHANISM OF ACTION
• AAV particles were packaged with a novel and proprietary vector construct that expresses a nonfunctional,non-coding (nc)RNA, HBV “Hijack RNA”, under a strong promoter (Fig. 1).
• Open reading frame (ORF) of HBV Hijack RNA is derived from the negative strand of human
caspase-9 (casp-9) coding region, and it is flanked between the HBV epsilon signals (Fig. 2).
• HBV epsilon signal is the recognition sequence that is specific to HBV pol. The reverse
transcriptase domain of HBV pol (HBV pol/RT) recognizes the Hijack RNA through these sequences and reversely transcribes it into a double stranded (ds)DNA that codes for casp-9, driven by a strong promoter (Fig. 3).
• The dsDNA engages with host polymerases to overexpress casp-9 and induce apoptosis of the
infected cell (Fig. 4A).
• In an uninfected cell, without the presence of HBV pol, Hijack RNA would be non-functional and be degraded (Fig. 4B).
• Expression of casp-9 were examined in AAV2-treated HepG2 and the HBV-infected HepAD39 cell lines.
• HBV-infected and uninfected hepatoma cell lines and primary human hepatocytes (PHH) were
treated with AAV2 particles expressing Hijack RNA “test AAV” or green fluorescent protein (GFP)
• To validate the mechanism of action, HBV-infected HepAD38 cells were treated with the test AAV in the presence or absence of RT inhibitors tenofovir or entecavir, casp-9-specific inhibitor Z-LEHDFMK or pan-caspase inhibitor Z-VAD-FMK (Fig. 4C). Cell viability and proliferation were evaluated by Chemometec NC-200 and FACS analysis using PI/Annexin V and TUNEL assays daily.
• HBV-transgenic mice, which constitutively express HBV from kidney and liver cells, received
intraperitoneal injections with 1011 AAV8 particles packaged with Hijack RNA under strong EF1a
promoter (DRS1-AAV8) or liver-specific TBG promoter (DRS2-AAV8), or GFP expressing
mock/control vector (Fig. 5). Day 14 post-injection, liver and kidney tissues were evaluated.
Weekly liver enzymatic activities (ALT and AST) were monitored.
Finding 1: Test vector selectively increased casp-9 levels in HBV infected cells
• There was a 254% increase in casp-9 levels in the treated HBV-infected, but not uninfected, cells (Fig. 6A).
• Casp-9 inhibitor salvaged the Hijack RNA-mediated infected cell death as demonstrated by expansion of viable cells by 10-20% (Fig. 6B).
Finding 2: HBV Hijack RNA selectively kills HBV-infected or HBV pol expressing cells
• Mean cell death in a variety of HBV-producing cells was 92% (ranging 88.6% to 95.8%), by day 4 (Fig. 7A-7C).
• No significant cell death was observed in uninfected cells (Fig. 7A-7C).
• RT and pan-caspase inhibitors individually prevented cell death in AAV-treated infected cells (Fig. 7D).
Finding 3: Mouse liver demonstrated Casp-9 overexpression in HBV-infected hepatocytes
treated with Hijack RNA AAV
• Casp-9 IHC staining showed extensive casp-9 overexpression in DRS1-AAV and DRS2-AAV treated, but not in GFPAAV treated or untreated mice liver tissue.
Finding 4: Hijack RNA AAV induced extensive neutrophil infiltration indicating HBV-infected
• Diffuse neutrophil infiltration indicating an inflammatory reaction to HBV-infected hepatocytes in mice treated with Hijack RNA AAV.
• Untreated mice or mice treated with GFP AAV control vector exhibited no evidence of inflammation
Finding 5: Increased liver enzymes in mice treated with HBV Hijack RNA AAV indicate
• AST levels increased 2.2 fold and 1.8 fold in mice treated with AAV-DRS1 and AAV-DRS2, respectively compared to GFP-AAV treated and untreated mice at week 4.
• ALT levels increased 1.4 fold in both treatment groups compared to GFP-AAV treated and untreated mice.
• Hijacking HBV pol to express casp-9 induces significant cell death in HBV-infected but not in HBVuninfected cells in vitro.
• Reverse transcriptase and caspase inhibition abrogated cell death, validating the hypothesized
mechanism of action.
• Data from in vivo studies demonstrate that HBV Hijack RNA induces apoptosis of HBV-infected
hepatocytes resulting in inflammation and increased liver enzymes.
• However, transgenic mouse models are inherently limited to study the potential for HBV cure
since it is impossible to eradicate HBV in animals that constitutively expresses the HBV genome
in every hepatocyte.
• These results demonstrate a novel mechanism of action for a potential cure for HBV infection.
• Additional in vitro and in vivo studies are in progress.
See discussions, stats, and author profiles for this publication
For research updates and news, please enter your email address in the field below.
©2020 | Seraph Research Institute
Individualized Research Team Give